1 citations
,
March 2003 in “Journal of Investigative Dermatology” Early sunburn treatment with certain inhibitors may reduce skin cancer risk.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
4 citations
,
January 1996 in “PubMed” 8 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
April 2023 in “Journal of Investigative Dermatology” Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly” January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
26 citations
,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
New treatments for skin diseases in 1979 showed promising results with fewer side effects.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
April 2011 in “Reactions Weekly” January 2026 in “Nutrición Hospitalaria” Many drugs can cause lipid metabolism issues, and labels need better warnings.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
14 citations
,
March 2014 in “Journal of the Society of Cosmetic Scientists of Korea” Some Korean herb extracts can reduce inflammation and are safe for skin use.
March 2026 in “British Journal of Dermatology”
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
1 citations
,
January 2017 in “International journal of trichology” Diphenylcyclopropenone (DPCP) effectively treated both alopecia areata and verruca vulgaris.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
9 citations
,
January 2019 in “International Journal of Trichology” Combining calcipotriol with mometasone is more effective for treating alopecia areata than using mometasone alone.